Heart Disease Trial, Recruiting NCT06595992 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06595992
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are at least 18 years old
  • People who are willing and able to give their informed consent to take part in the study
  • People who have been diagnosed with moderate aortic valve disease, confirmed by an ultrasound of the heart (echocardiogram)

Who may not be able to join:

  • People who have severe aortic valve disease (confirmed by heart ultrasound), or who have heart surgery planned, or who are likely to need heart surgery within the next 6 months
  • People who have already had a specific minimally invasive heart valve procedure called transfemoral transcatheter aortic valve replacement (TAVR/TAVI)
  • People whose life expectancy is less than 12 months due to a condition other than heart disease, such as cancer, chronic liver disease, chronic kidney disease, or advanced lung disease
  • People with severe dementia who are unable to sign a consent form, care for themselves, or attend the required study visits
  • People who are currently experiencing acute pulmonary oedema (sudden fluid build-up in the lungs) or cardiogenic shock (when the heart suddenly cannot pump enough blood) (confirm with trial site)
  • People whom the study doctor considers unsuitable to participate or to complete the required follow-up visits, for medical, social, or psychological reasons
  • People who are currently taking part in another randomised clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jianan Wang, Dorctor, Second Affiliated Hospital of Zhejiang University, School of Medicine

Phone: 086-571-87784705

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 September 2024
Est. completion
1 January 2034

Where this trial is recruiting

🇨🇳 China

Primary endpoints

All cause mortality; Re-hospitalization related to heart failure.; Aortic valve replacement; Stroke

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov